Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health, announced findings from an early cost-effectiveness modeling study that aimed to assess the total costs and health outcomes associated with the use of an investigational RNA-FIT biomarker panel versus multi-target stool DNA (mt-sDNA), fecal immunochemical test (FIT), and colonoscopy… Continue reading Geneoscopy Cost-Effectiveness Modeling Data Demonstrates Potential to Reduce Colorectal Cancer Cases and Deaths